Clinical Trials
11 trialsNCT01676753 2022-09-21
Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT01711528 2018-05-11
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01624441 2018-03-30
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01515176 2018-03-15
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00871910 2017-10-23
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01783171 2017-08-22
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01580228 2017-02-23
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00732810 2015-08-05
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00871663 2015-04-20
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01650727 2015-02-10
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01096342 2014-06-18
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed